Professor Zhiming Li: Addressing the Challenges of NK/T-Cell Lymphoma with a China-Specific Approach | 2026 CACA Western Integrated Oncology Conference

Professor Zhiming Li: Addressing the Challenges of NK/T-Cell Lymphoma with a China-Specific Approach | 2026 CACA Western Integrated Oncology Conference

To further promote the expansion, equitable distribution, and accessibility of high-quality cancer care resources, and to enhance the academic and clinical capabilities of oncology care in western China and at the grassroots level, the 2026 CACA Western Integrated Oncology Conference was successfully held in Chengdu on April 18, 2026. The conference provided a high-level platform for academic exchange and translational collaboration in oncology.
Professor Yuankai Shi: Thirty-Five Years of Iterative Innovation—Lymphoma Leading China’s Modernization in Oncology Drug Therapy | 2026 CACA Western Integrative Oncology Conference

Professor Yuankai Shi: Thirty-Five Years of Iterative Innovation—Lymphoma Leading China’s Modernization in Oncology Drug Therapy | 2026 CACA Western Integrative Oncology Conference

As a bellwether for innovation in oncology drug therapy, the evolution of lymphoma treatment reflects the broader trajectory of modernization in Chinese oncology. From the introduction of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in 1992—laying the foundation for chemotherapy—to successive breakthroughs in targeted therapy, immunotherapy, and cellular therapy, China’s lymphoma care has undergone 35 years of transformation, progressing from “following” to “running alongside,” and now to “leading.”
Professor Yu Wang: Innovations and Advances in Transplantation Strategies for AML

Professor Yu Wang: Innovations and Advances in Transplantation Strategies for AML

Acute myeloid leukemia (AML) is a heterogeneous group of malignant clonal disorders originating from myeloid stem cells, characterized by significant biological diversity and generally poor prognosis. The global disease burden of AML continues to rise, with the age-standardized incidence increasing by 87.3% between 1990 and 2021, underscoring the urgent need for improved therapeutic strategies.
North–South Summit 2026 | Professor Jia Wang: In the Era of Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer—Is Platinum Still Essential?

North–South Summit 2026 | Professor Jia Wang: In the Era of Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer—Is Platinum Still Essential?

In the era of neoadjuvant immunotherapy for triple-negative breast cancer (TNBC), an important clinical question has emerged: is platinum still indispensable? During the “Deep Dive” session at the 8th North–South Breast Cancer Forum, Professor Jia Wang from Zhongshan Hospital, Dalian University presented an in-depth analysis of this issue. Drawing on treatment goals, mechanistic rationale, clinical evidence, and individualized strategies, she systematically reviewed the role and challenges of platinum agents in neoadjuvant immunotherapy for TNBC and proposed future directions toward precision “de-escalation” therapy.
Annals of Oncology: Academician Binghe Xu and Professor Tao Sun Report the OPTIMAL Study—Oral Paclitaxel Demonstrates Non-Inferiority to Intravenous Therapy in HER2-Negative Advanced Breast Cancer

Annals of Oncology: Academician Binghe Xu and Professor Tao Sun Report the OPTIMAL Study—Oral Paclitaxel Demonstrates Non-Inferiority to Intravenous Therapy in HER2-Negative Advanced Breast Cancer

On March 14, 2026, the international oncology journal Annals of Oncology (2025 IF: 65.4), the official journal of the European Society for Medical Oncology (ESMO), published the results of the international multicenter phase III OPTIMAL trial (NCT03315364). The study was led by Academician Binghe Xu (first author) from the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, and Professor S-B. Kim (corresponding author), with key contributions from Professor Tao Sun (Liaoning Cancer Hospital) and Professor H. Jeong (Asan Medical Center, University of Ulsan College of Medicine), among other international collaborators. For the first time, the study demonstrated that oral paclitaxel (DHP107) is non-inferior to weekly intravenous paclitaxel in first-line treatment of HER2-negative recurrent or metastatic breast cancer, with lower neurotoxicity and greater convenience—offering patients a safer and more accessible therapeutic option.
Deciphering VEXAS Syndrome: From UBA1 Somatic Mutations to Precision Management and Allo-HSCT

Deciphering VEXAS Syndrome: From UBA1 Somatic Mutations to Precision Management and Allo-HSCT

During the recent workshop "Focus on Allogeneic HSCT in Myelodysplastic Syndromes," Professor Fabio Ciceri (IRCCS San Raffaele Scientific Institute / Vita-Salute San Raffaele University), Chair of the EBMT Scientific Council and the Acute Leukemia Working Party (ALWP), provided a comprehensive overview of "Contemporary Approaches to VEXAS." He systematically detailed the genetic foundations, clinical progression, and multidimensional therapeutic landscape of this complex disease.
Professor Ming Hou: From “Following” to “Leading”—Key Updates in the 2025 Chinese Guidelines for Adult Immune Thrombocytopenia

Professor Ming Hou: From “Following” to “Leading”—Key Updates in the 2025 Chinese Guidelines for Adult Immune Thrombocytopenia

In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026. Centered on advances in the diagnosis and treatment of thrombotic and hemostatic disorders, as well as hematologic malignancies and immunology, the meeting highlighted cutting-edge developments and evolving clinical strategies.